Literature DB >> 19589010

Automated messaging to improve compliance with diabetes test monitoring.

Stephen F Derose1, Randall K Nakahiro, Frederick H Ziel.   

Abstract

OBJECTIVES: To evaluate the use of automated systems to prompt patients with diabetes mellitus to obtain overdue laboratory tests for its effectiveness in promoting test compliance and to compare letters, telephone messages, and combinations. STUDY
DESIGN: Randomized controlled trial.
METHODS: All subjects (N = 13,057) were adult members of Southern California Kaiser Permanente with diabetes and with no record of glycosylated hemoglobin, low-density lipoprotein cholesterol, and urinary microalbumin tests in more than 1 year. The effectiveness of automated telephone calls and letters was compared versus a no-contact control group using the following 5 intervention groups: letter, call, letter that is followed by a call 4 weeks later, call that is followed by a letter 4 weeks later, and letter-call-letter combination. Messages were in English and in Spanish. Adherence to all testing was compared at 8 weeks and 12 weeks after initial contact using chi(2) test and logistic regression analysis.
RESULTS: The proportions of each study group compliant with all tests were 18% to 19% among controls, 21% for a letter or a call, 25% for a letter-call or call-letter, and 26% for a letter-call-letter; letter-call and call-letter were significantly different versus controls (P <.001), and letter-call-letter was not significantly different versus letter-call. Older age was associated with compliance (P <.001).
CONCLUSIONS: The pairing of automated letters and telephone calls in any order was more effective than any single intervention in promoting compliance with diabetes monitoring tests. The relative cost of the letter-call and call-letter approaches to outreach should be considered to determine which is preferred in any given situation.

Entities:  

Mesh:

Year:  2009        PMID: 19589010

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  7 in total

1.  Predictors of non-response and non-compliance in African American lupus patients: Findings from the Balancing Lupus Experiences with Stress Strategies (BLESS) Study.

Authors:  Edith M Williams; Jiajia Zhang; Jie Zhou; Diane Kamen; James C Oates
Journal:  Int J Med Biomed Sci       Date:  2014-02

Review 2.  The reality of dietary compliance in the management of phenylketonuria.

Authors:  Anita MacDonald; Hulya Gokmen-Ozel; Margreet van Rijn; Peter Burgard
Journal:  J Inherit Metab Dis       Date:  2010-04-07       Impact factor: 4.982

Review 3.  Effective Self-Management Interventions for Patients With Lupus: Potential Impact of Peer Mentoring.

Authors:  Edith M Williams; Leonard Egede; Trevor Faith; James Oates
Journal:  Am J Med Sci       Date:  2017-02-03       Impact factor: 2.378

Review 4.  The impact of interventions on appointment and clinical outcomes for individuals with diabetes: a systematic review.

Authors:  Lynn Nuti; Ayten Turkcan; Mark A Lawley; Lingsong Zhang; Laura Sands; Sara McComb
Journal:  BMC Health Serv Res       Date:  2015-09-02       Impact factor: 2.655

Review 5.  Social Determinants of Health, the Chronic Care Model, and Systemic Lupus Erythematosus.

Authors:  Edith M Williams; Kasim Ortiz; Teri Browne
Journal:  Int J Chronic Dis       Date:  2014-01-05

6.  Intervention to Improve Quality of life for African-AmericaN lupus patients (IQAN): study protocol for a randomized controlled trial of a unique a la carte intervention approach to self-management of lupus in African Americans.

Authors:  Edith M Williams; Kate Lorig; Saundra Glover; Diane Kamen; Sudie Back; Anwar Merchant; Jiajia Zhang; James C Oates
Journal:  BMC Health Serv Res       Date:  2016-08-02       Impact factor: 2.655

7.  A randomized controlled trial of an automated telephone intervention to improve blood pressure control.

Authors:  Teresa N Harrison; Timothy S Ho; Joel Handler; Michael H Kanter; Ruthie A Goldberg; Kristi Reynolds
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-07-12       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.